Literature DB >> 22638841

Chronic urticaria.

Torsten Zuberbier1.   

Abstract

Chronic urticaria is defined as case of spontaneous wheals and/or angioedema persisting for a period of at least six weeks. The disease has an average duration of three to five years and is strongly associated with a decrease of quality of life and performance. Current international guidelines recommend the use of non-sedating antihistamines as the first choice in therapy and up-dosing these up to fourfold in cases of non-response. Alternative treatments for the afflicted who do not respond to antihistamine-treatment are also available but are not approved for use on urticaria.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22638841     DOI： 10.1007/s11882-012-0270-7

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN： 1529-7322            Impact factor:   4.806


  8 in total

1.  Chronic urticaria: a mystery.

Authors:  P D Pigatto; R H Valsecchi
Journal:  Allergy       Date:  2000-03       Impact factor: 13.146

2.  Effects of low pseudoallergen diet on urticarial activity and leukotriene levels in chronic urticaria.

Authors:  Gulsen Akoglu; Nilgun Atakan; Banu Cakır; Omer Kalayci; Mutlu Hayran
Journal:  Arch Dermatol Res       Date:  2011-12-27       Impact factor: 3.017

Review 3.  Pharmacological rationale for the treatment of chronic urticaria with second-generation non-sedating antihistamines at higher-than-standard doses.

Authors:  T Zuberbier
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-07-29       Impact factor: 6.166

Review 4.  Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report.

Authors:  M Maurer; K Weller; C Bindslev-Jensen; A Giménez-Arnau; P J Bousquet; J Bousquet; G W Canonica; M K Church; K V Godse; C E H Grattan; M W Greaves; M Hide; D Kalogeromitros; A P Kaplan; S S Saini; X J Zhu; T Zuberbier
Journal:  Allergy       Date:  2010-11-17       Impact factor: 13.146

5.  EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria.

Authors:  T Zuberbier; R Asero; C Bindslev-Jensen; G Walter Canonica; M K Church; A M Giménez-Arnau; C E H Grattan; A Kapp; M Maurer; H F Merk; B Rogala; S Saini; M Sánchez-Borges; P Schmid-Grendelmeier; H Schünemann; P Staubach; G A Vena; B Wedi
Journal:  Allergy       Date:  2009-10       Impact factor: 13.146

6.  EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria.

Authors:  T Zuberbier; R Asero; C Bindslev-Jensen; G Walter Canonica; M K Church; A Giménez-Arnau; C E H Grattan; A Kapp; H F Merk; B Rogala; S Saini; M Sánchez-Borges; P Schmid-Grendelmeier; H Schünemann; P Staubach; G A Vena; B Wedi; M Maurer
Journal:  Allergy       Date:  2009-10       Impact factor: 13.146

7.  Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper.

Authors:  I Baiardini; P J Bousquet; Z Brzoza; G W Canonica; E Compalati; A Fiocchi; W Fokkens; R G van Wijk; S La Grutta; C Lombardi; M Maurer; A M Pinto; E Ridolo; G E Senna; I Terreehorst; A Todo Bom; J Bousquet; T Zuberbier; F Braido
Journal:  Allergy       Date:  2009-11-20       Impact factor: 13.146

8.  Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial.

Authors:  M Magerl; D Pisarevskaja; R Scheufele; T Zuberbier; Marcus Maurer
Journal:  Allergy       Date:  2009-10-01       Impact factor: 13.146
  8 in total
  4 in total

1.  Healthcare Services Utilization and Drug Use in Patients with Chronic Urticaria.

Authors:  Guy Shalom; Dennis Linder; Doron Comaneshter; Alexandra Nathan; Haim Bitterman; Nancy Agmon-Levin; Arnon D Cohen
Journal:  J Invest Dermatol       Date:  2015-08-24       Impact factor: 8.551

Review 2.  Oral H1 antihistamines as monotherapy for eczema.

Authors:  Christian J Apfelbacher; Esther J van Zuuren; Zbys Fedorowicz; Aldrin Jupiter; Uwe Matterne; Elke Weisshaar
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

3.  The care pathway for children with urticaria, angioedema, mastocytosis.

Authors:  Giuliana Ferrante; Valeria Scavone; Maria Concetta Muscia; Emilia Adrignola; Giovanni Corsello; Giovanni Passalacqua; Stefania La Grutta
Journal:  World Allergy Organ J       Date:  2015-02-02       Impact factor: 4.084

4.  Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria.

Authors:  Jonathan Graham; Doreen McBride; Donald Stull; Anna Halliday; Stamatia Theodora Alexopoulos; Maria-Magdalena Balp; Matthew Griffiths; Ion Agirrezabal; Torsten Zuberbier; Alan Brennan
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.